Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders

[1] Bannon MJ(2005)The dopamine transporter: role in neurotoxicity and human disease Toxicol Appl Pharmacol 204 355-360

[2] Vaughan RA(2013)Mechanisms of dopamine transporter regulation in normal and disease states Trends Pharmacol Sci 34 489-496

[3] Foster JD(2017)Molecular imaging to track Parkinson's disease and atypical parkinsonisms: new imaging frontiers Mov Disord 32 181-192

[4] Strafella AP(2009)Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria Lancet Neurol 8 1150-1157

[5] Bohnen NI(2014)Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials BMJ Open 4 1397-1406

[6] Perlmutter JS(2007)Quantification of dopamine transporter binding using 18FFP-beta-CIT and positron emission tomography J Cereb Blood Flow Metab 27 1065-1073

[7] Dickson DW(2012)Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I J Nucl Med 53 217-222

[8] Braak H(2014)Quantification of dopamine transporter density with 18FFECNT PET in healthy humans Nucl Med Biol 41 1521-1530

[9] Duda JE(1998)Dopamine transporter imaging with fluorine-18-FPCIT and PET J Nucl Med 39 90-1487

[10] O'Brien JT(2019)The story of the dopamine transporter PET tracer LBT-999: from conception to clinical use Front Med 6 1480-682

[1] Bannon MJ(2005)The dopamine transporter: role in neurotoxicity and human disease Toxicol Appl Pharmacol 204 355-360

[2] Vaughan RA(2013)Mechanisms of dopamine transporter regulation in normal and disease states Trends Pharmacol Sci 34 489-496

[3] Foster JD(2017)Molecular imaging to track Parkinson's disease and atypical parkinsonisms: new imaging frontiers Mov Disord 32 181-192

[4] Strafella AP(2009)Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria Lancet Neurol 8 1150-1157

[5] Bohnen NI(2014)Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials BMJ Open 4 1397-1406

[6] Perlmutter JS(2007)Quantification of dopamine transporter binding using 18FFP-beta-CIT and positron emission tomography J Cereb Blood Flow Metab 27 1065-1073

[7] Dickson DW(2012)Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I J Nucl Med 53 217-222

[8] Braak H(2014)Quantification of dopamine transporter density with 18FFECNT PET in healthy humans Nucl Med Biol 41 1521-1530

[9] Duda JE(1998)Dopamine transporter imaging with fluorine-18-FPCIT and PET J Nucl Med 39 90-1487

[10] O'Brien JT(2019)The story of the dopamine transporter PET tracer LBT-999: from conception to clinical use Front Med 6 1480-682